Novartis AG
Close on Oct 30, 2026Market cap $306.81BP/E 22.5Yield –
Novartis 5. Established Brands & Contract Manufacturing by Year
5. Established Brands & Contract Manufacturing ($M)
Novartis 5. Established Brands & Contract Manufacturing: $12,457M in FY2025, down 7.0% from a year earlier.
Where the FY2025 figure comes from
“|| Total established brands 4 | 12 457 | 13 401 | -7 | -7”
Source: Novartis Form 6-K (0001114448-26-000007) ↗
Reported in Form 6-K (Net sales by therapeutic area) & Form 20-F.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | 5. Established Brands & Contract Manufacturing ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 12,457 | -7.0% | Novartis Form 6-K (0001114448-26-000007) ↗ |
| FY2024 | Dec 31, 2024 | 13,401 | -9.1% | Novartis Form 6-K (0001114448-26-000007) ↗ |
| FY2023 | Dec 31, 2023 | 14,750 | -7.5% | Novartis Form 6-K (0001370368-25-000007) ↗ |
| FY2022 | Dec 31, 2022 | 15,949 | – | Novartis Form 6-K (0001370368-24-000007) ↗ |
Breakdown
What makes up 5. Established Brands & Contract Manufacturing
- Therapeutic Area Revenue Growth at Constant Currencies (% cc)-7.0% · FY2025
- Therapeutic Area Revenue Growth in USD (% USD)-7.0% · FY2025
- Sandostatin Group (octreotide — neuroendocrine tumors & acromegaly)1,213 · FY2025
- Exforge Group (amlodipine/valsartan — hypertension)727 · FY2025
- Promacta / Revolade (eltrombopag — immune thrombocytopenia ITP & aplastic anemia)1,636 · FY2025
- Tasigna (nilotinib — chronic myeloid leukemia CML)1,104 · FY2025
- Diovan Group (valsartan — hypertension & heart failure)604 · FY2025
- Piqray / Vijoice (alpelisib — PIK3CA-mutated breast cancer & PROS syndrome)382 · FY2025
- Myfortic (mycophenolic acid — prevention of organ transplant rejection)–
- Lucentis (ranibizumab — Wet AMD, Ex-US)643 · FY2025
- Kymriah (tisagenlecleucel — Hematologic CAR-T Cell Therapy)381 · FY2025
- Contract Manufacturing1,419 · FY2025
- Other Established Brands6,983 · FY2025
Cite this data
StockData. (2026). Novartis 5. Established Brands & Contract Manufacturing ($M), annual FY2022–FY2025 [Data set]. Compiled from Novartis SEC filings and investor materials. https://stockdatahq.com/stocks/nvs/kpis/ta-established
See every metric in the Novartis KPI table. Data updated Nov 2, 2026.